A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-2027
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK ; day:31 ; month:12 ; year:2016 ; pages:1-13
PharmacoEconomics ; (31.12.2016), 1-13

Schlagwort
Atemwegskrankheit
Atemnot

Urheber
Rinciog, C.
Beteiligte Personen und Organisationen
Watkins, M.
Chang, S.
Maher, T. M.
LeReun, C.
Esser, D.
Diamantopoulos, A.
SpringerLink (Online service)

DOI
10.1007/s40273-016-0480-2
URN
urn:nbn:de:1111-201701283536
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:55 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Rinciog, C.
  • Watkins, M.
  • Chang, S.
  • Maher, T. M.
  • LeReun, C.
  • Esser, D.
  • Diamantopoulos, A.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update

Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report

Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report

Verbundene Objekte